If you prescribe peptides, work with 503A or 503B compounders, or run telehealth in longevity medicine, the ground under your practice is moving. FDA compounding categories, PCAC recommendations, DEA scheduling actions, state pharmacy inspections, HIPAA enforcement, and CMS telehealth rules are all shifting month by month.
Missing one of those changes is not a paperwork problem. It can invalidate a protocol you are actively prescribing, and it can put your practice, your license, and your patients at real risk.
Most clinics track regulation the same way they track studies: irregularly, when something breaks. The result is a lag between what is legal today and what the practice is actually doing.
Regulatory Intelligence at Scriptura runs a daily scan across the sources that actually matter to longevity practice: FDA warning letters and 483s, Federal Register notices touching compounding or pharmacy, DEA news and scheduling, HIPAA and OCR enforcement, CMS telehealth policy, Texas DSHS and Texas Medical Board (and the state boards for every state we operate in), the FDA LDT rule and enforcement, and DSHEA supplement enforcement. What lands in front of the prescriber is a short, plain English summary of what changed, who it affects, and what to do next.
You do not have to read the Federal Register at midnight anymore.
Written by the Scriptura Health clinical team. For clinician review only. Not medical or legal advice.